These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

919 related articles for article (PubMed ID: 17612779)

  • 21. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
    Van Poznak C; Hannon RA; Mackey JR; Campone M; Apffelstaedt JP; Clack G; Barlow D; Makris A; Eastell R
    J Clin Oncol; 2010 Feb; 28(6):967-75. PubMed ID: 20065185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
    Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harpe K
    Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):269-73. PubMed ID: 15059505
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
    Miller PD; Roux C; Boonen S; Barton IP; Dunlap LE; Burgio DE
    J Bone Miner Res; 2005 Dec; 20(12):2105-15. PubMed ID: 16294264
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tibolone and osteoporosis.
    Lazovic G; Radivojevic U; Milosevic V; Lazovic A; Jeremic K; Glisic A
    Arch Gynecol Obstet; 2007 Dec; 276(6):577-81. PubMed ID: 17605023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.
    Boonen S; Lorenc RS; Wenderoth D; Stoner KJ; Eusebio R; Orwoll ES
    Bone; 2012 Sep; 51(3):383-8. PubMed ID: 22750403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risedronate reduces intracortical porosity in women with osteoporosis.
    Borah B; Dufresne T; Nurre J; Phipps R; Chmielewski P; Wagner L; Lundy M; Bouxsein M; Zebaze R; Seeman E
    J Bone Miner Res; 2010 Jan; 25(1):41-7. PubMed ID: 19580469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of risedronate on osteocyte viability and bone turnover in paired iliac bone biopsies from early postmenopausal women.
    Qiu S; Phipps RJ; Ebetino FH; Palnitkar S; Sudhaker Rao D
    Calcif Tissue Int; 2010 Nov; 87(5):392-7. PubMed ID: 20809096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
    Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
    J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.
    Boonen S; McClung MR; Eastell R; El-Hajj Fuleihan G; Barton IP; Delmas P
    J Am Geriatr Soc; 2004 Nov; 52(11):1832-9. PubMed ID: 15507059
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.
    Recker RR; Delmas PD; Halse J; Reid IR; Boonen S; García-Hernandez PA; Supronik J; Lewiecki EM; Ochoa L; Miller P; Hu H; Mesenbrink P; Hartl F; Gasser J; Eriksen EF
    J Bone Miner Res; 2008 Jan; 23(1):6-16. PubMed ID: 17892374
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women.
    Tanriverdi HA; Barut A; Sarikaya S
    Eur J Obstet Gynecol Reprod Biol; 2005 May; 120(1):63-8. PubMed ID: 15866088
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
    Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
    J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
    Lazzari AA; Dussault PM; Thakore-James M; Gagnon D; Baker E; Davis SA; Houranieh AM
    Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
    Gamsjaeger S; Buchinger B; Zoehrer R; Phipps R; Klaushofer K; Paschalis EP
    Bone; 2011 Dec; 49(6):1160-5. PubMed ID: 21893225
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis.
    Harrington JT; Ste-Marie LG; Brandi ML; Civitelli R; Fardellone P; Grauer A; Barton I; Boonen S
    Calcif Tissue Int; 2004 Feb; 74(2):129-35. PubMed ID: 14648009
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
    AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The relationship between regional bone turnover measured using 18F-fluoride positron emission tomography and changes in BMD is equivalent to that seen for biochemical markers of bone turnover.
    Frost ML; Cook GJ; Blake GM; Marsden PK; Fogelman I
    J Clin Densitom; 2007; 10(1):46-54. PubMed ID: 17289526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures.
    Ohtori S; Akazawa T; Murata Y; Kinoshita T; Yamashita M; Nakagawa K; Inoue G; Nakamura J; Orita S; Ochiai N; Kishida S; Takaso M; Eguchi Y; Yamauchi K; Suzuki M; Aoki Y; Takahashi K
    J Clin Neurosci; 2010 Feb; 17(2):209-13. PubMed ID: 20044258
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.
    Bone HG; McClung MR; Roux C; Recker RR; Eisman JA; Verbruggen N; Hustad CM; DaSilva C; Santora AC; Ince BA
    J Bone Miner Res; 2010 May; 25(5):937-47. PubMed ID: 19874198
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
    Choo R; Lukka H; Cheung P; Corbett T; Briones-Urbina R; Vieth R; Ehrlich L; Kiss A; Danjoux C
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1239-45. PubMed ID: 23265571
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.